Zymeworks Inc
ZYME19.085USD
-0.035-0.18%
Fechamento 10/31, 16:00（ET）Cotações atrasadas em 15 min
1.34BValor de mercado
PerdaP/L TTM
Mais detalhes de Zymeworks Inc Empresa
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
Informações de Zymeworks Inc
Código da empresaZYME
Nome da EmpresaZymeworks Inc
Data de listagemJun 24, 2019
CEOMr. Kenneth H. (Ken) Galbraith
Número de funcionários280
Tipo de títulosOrdinary Share
Fim do ano fiscalJun 24
Endereço108 Patriot Drive, Suite A
CidadeMIDDLETOWN
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal19709
Telefone13022748744
Sitehttps://www.zymeworks.com/
Código da empresaZYME
Data de listagemJun 24, 2019
CEOMr. Kenneth H. (Ken) Galbraith
Executivos da empresa Zymeworks Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Ms. Leone D. Patterson, CPA
Ms. Leone D. Patterson, CPA
Chief Financial Officer, Chief Business Officer, Executive Vice President
Chief Financial Officer, Chief Business Officer, Executive Vice President
--
--
Mr. Kenneth H. (Ken) Galbraith
Mr. Kenneth H. (Ken) Galbraith
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
--
--
Dr. Neil Gallagher, M.D., Ph.D.
Dr. Neil Gallagher, M.D., Ph.D.
Independent Director
Independent Director
--
--
Mr. Carlos E. Campoy
Mr. Carlos E. Campoy
Independent Director
Independent Director
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Robert E. (Bob) Landry
Mr. Robert E. (Bob) Landry
Independent Director
Independent Director
--
--
Mr. Gregory A. Ciongoli
Mr. Gregory A. Ciongoli
Independent Director
Independent Director
--
--
Dr. Sabeen Mekan, M.D.
Dr. Sabeen Mekan, M.D.
Senior Vice President - Clinical Development
Senior Vice President - Clinical Development
--
--
Dr. Kelvin M. Neu ,M.D.
Dr. Kelvin M. Neu ,M.D.
Independent Director
Independent Director
--
--
Mr. Scott Platshon
Mr. Scott Platshon
Independent Director
Independent Director
--
--
Dr. Alessandra Cesano, M.D., Ph.D.
Dr. Alessandra Cesano, M.D., Ph.D.
Independent Director
Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 8 de out
Atualizado em: qua, 8 de out
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
EcoR1 Capital, LLC
30.56%
Rubric Capital Management LP
6.27%
BVF Partners L.P.
5.73%
Redmile Group, LLC
5.52%
Morgan Stanley & Co. LLC
4.82%
Outro
47.10%
Investidores
Investidores
Proporção
EcoR1 Capital, LLC
30.56%
Rubric Capital Management LP
6.27%
BVF Partners L.P.
5.73%
Redmile Group, LLC
5.52%
Morgan Stanley & Co. LLC
4.82%
Outro
47.10%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
50.55%
Investment Advisor
24.39%
Hedge Fund
18.92%
Research Firm
5.96%
Private Equity
1.70%
Individual Investor
0.81%
Venture Capital
0.45%
Pension Fund
0.28%
Sovereign Wealth Fund
0.27%
Participação acionária institucional
Atualizado em: qua, 1 de out
Atualizado em: qua, 1 de out
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q3
390
77.28M
102.81%
+1.24M
2025Q2
383
76.90M
102.73%
+2.83M
2025Q1
400
71.70M
97.61%
-1.37M
2024Q4
389
68.69M
99.73%
-8.79M
2024Q3
388
74.13M
105.03%
-25.13M
2024Q2
387
74.77M
106.29%
-27.88M
2024Q1
389
74.54M
106.20%
-28.73M
2023Q4
388
72.09M
103.65%
-29.69M
2023Q3
376
69.54M
103.06%
-33.91M
2023Q2
364
70.30M
109.70%
-27.74M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
EcoR1 Capital, LLC
22.97M
30.56%
+5.09M
+28.44%
Jun 30, 2025
Rubric Capital Management LP
4.71M
6.27%
+372.11K
+8.58%
Jun 30, 2025
BVF Partners L.P.
4.31M
5.73%
--
--
Jun 30, 2025
Redmile Group, LLC
4.15M
5.52%
-638.32K
-13.33%
Jun 30, 2025
Morgan Stanley & Co. LLC
3.62M
4.82%
+317.19K
+9.60%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.11M
4.14%
-287.50K
-8.46%
Jun 30, 2025
The Vanguard Group, Inc.
2.46M
3.27%
+694.76K
+39.45%
Jun 30, 2025
BNP Paribas Asset Management USA, Inc.
2.04M
2.71%
-158.63K
-7.22%
Jun 30, 2025
Blackstone Alternative Asset Management, L.P.
1.66M
2.2%
+274.20K
+19.83%
Jun 30, 2025
UBS Asset Management (Americas) LLC
1.46M
1.94%
-146.62K
-9.14%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 2 de nov
Atualizado em: dom, 2 de nov
Nome
Proporção
Tema Oncology ETF
1.55%
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
Federated Hermes MDT Small Cap Core ETF
0.21%
iShares Micro-Cap ETF
0.18%
WisdomTree US SmallCap Quality Growth Fund
0.13%
Invesco Nasdaq Biotechnology ETF
0.13%
ProShares Ultra Nasdaq Biotechnology
0.13%
iShares Biotechnology ETF
0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
0.1%
SPDR S&P International Small Cap ETF
0.09%
Ver Mais
Tema Oncology ETF
Proporção1.55%
Virtus LifeSci Biotech Clinical Trials ETF
Proporção0.94%
Federated Hermes MDT Small Cap Core ETF
Proporção0.21%
iShares Micro-Cap ETF
Proporção0.18%
WisdomTree US SmallCap Quality Growth Fund
Proporção0.13%
Invesco Nasdaq Biotechnology ETF
Proporção0.13%
ProShares Ultra Nasdaq Biotechnology
Proporção0.13%
iShares Biotechnology ETF
Proporção0.12%
iShares MSCI USA Small-Cap Min Vol Factor ETF
Proporção0.1%
SPDR S&P International Small Cap ETF
Proporção0.09%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
